Needham analyst Serge Belanger has maintained their bullish stance on OCUL stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Serge Belanger has given his Buy rating due to a combination of factors related to Ocular Therapeutix’s promising pipeline and upcoming clinical trial results. The company’s SOL-R phase 3 trial in wet age-related macular degeneration (wAMD) has completed randomization and is on track for results in the first half of 2027, while the HELIOS program in non-proliferative diabetic retinopathy/diabetic macular edema (NPDR/DME) is expected to start by the end of 2025.
The immediate focus for investors is the SOL-1 phase 3 trial results expected in the first quarter of 2026. This trial, conducted under a Special Protocol Assessment (SPA), aims to demonstrate statistical significance, which, along with SOL-R results, could support the approval of Axpaxli with a claim of superiority in duration compared to Eylea. The anticipation of these results and Axpaxli’s potential as a differentiated extended-duration treatment for retinal diseases underpin the Buy rating and a price target of $20.